{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:21:18Z","timestamp":1789694478920,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.medj.2024.07.015","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:09:18Z","timestamp":1723118958000},"page":"1424-1432.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study"],"prefix":"10.1016","volume":"5","author":[{"given":"Guoqing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.07.015_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese Classification of Esophageal Cancer, 12th Edition: Part I, 12th Edition","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"key":"10.1016\/j.medj.2024.07.015_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10388-024-01048-w","article-title":"Japanese Classification of Esophageal Cancer, 12th Edition: Part II, 12th Edition","volume":"21","author":"Doki","year":"2024","journal-title":"Esophagus"},{"key":"10.1016\/j.medj.2024.07.015_bib3","first-page":"3535","article-title":"Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer","volume":"31","author":"Yokota","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.medj.2024.07.015_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/atm-21-6931","article-title":"A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel\/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma","volume":"10","author":"Li","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.medj.2024.07.015_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10388-021-00864-8","article-title":"Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial","volume":"19","author":"Wang","year":"2022","journal-title":"Esophagus"},{"key":"10.1016\/j.medj.2024.07.015_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10147-017-1168-0","article-title":"Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer","volume":"23","author":"Yokota","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.015_bib7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10388-017-0580-x","article-title":"Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma","volume":"14","author":"Hamamoto","year":"2017","journal-title":"Esophagus"},{"key":"10.1016\/j.medj.2024.07.015_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11748-023-01934-7","article-title":"Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil","volume":"71","author":"Nakajima","year":"2023","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.medj.2024.07.015_bib9","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1007\/s11605-023-05876-6","article-title":"Neoadjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Borderline Resectable Esophageal Squamous Cell Carcinoma","volume":"27","author":"Hosogi","year":"2023","journal-title":"J.\u00a0Gastrointest. Surg."},{"key":"10.1016\/j.medj.2024.07.015_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ags3.12706","article-title":"Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T3 thoracic esophageal cancer","volume":"7","author":"Wakita","year":"2023","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.medj.2024.07.015_bib11","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1245\/s10434-019-08124-x","article-title":"Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma","volume":"27","author":"Suzuki","year":"2020","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.medj.2024.07.015_bib12","first-page":"LBA244","article-title":"Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial. 2024 ASCO Gastrointestinal","author":"Yin","year":"2024","journal-title":"Cancers Symposium"},{"key":"10.1016\/j.medj.2024.07.015_bib13","article-title":"Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2024.07.015_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1148\/radiology.146.2.6849089","article-title":"Computed tomography in the staging of esophageal carcinoma","volume":"146","author":"Picus","year":"1983","journal-title":"Radiology"},{"key":"10.1016\/j.medj.2024.07.015_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2214\/ajr.156.2.1898802","article-title":"Carcinoma of the esophagus: CT vs MR imaging in determining resectability","volume":"156","author":"Takashima","year":"1991","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.medj.2024.07.015_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/pmj.77.905.181","article-title":"Evaluation of local invasion by oesophageal carcinoma--a prospective study of prone computed tomography scanning","volume":"77","author":"Wayman","year":"2001","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.medj.2024.07.015_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1148\/radiology.155.1.3975398","article-title":"Esophageal carcinoma: CT findings","volume":"155","author":"Quint","year":"1985","journal-title":"Radiology"},{"key":"10.1016\/j.medj.2024.07.015_bib18","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00268-022-06568-z","article-title":"Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma","volume":"46","author":"Hirohata","year":"2022","journal-title":"World J. Surg."},{"key":"10.1016\/j.medj.2024.07.015_bib19","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.medj.2024.07.015_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doac031","article-title":"Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China","volume":"35","author":"Yang","year":"2022","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.medj.2024.07.015_bib21","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1245\/s10434-021-10121-y","article-title":"The \u201cReal R0\u201d: A Resection Margin Smaller Than 0.1\u00a0cm is Associated with a Poor Prognosis After Oncologic Esophagectomy","volume":"28","author":"St-Amour","year":"2021","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.medj.2024.07.015_bib22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jtcvs.2020.09.042","article-title":"Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"162","author":"Tang","year":"2021","journal-title":"J.\u00a0Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.medj.2024.07.015_bib23","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1245\/s10434-015-4412-8","article-title":"A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies","volume":"22","author":"Chao","year":"2015","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.medj.2024.07.015_bib24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/SLA.0b013e3182a6191d","article-title":"Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa","volume":"258","author":"Shapiro","year":"2013","journal-title":"Ann. Surg."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:39:52Z","timestamp":1773830392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024002976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666634024002976"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.015","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}